BUYOUT OF OBAGI MEDICAL - LAW FIRM SEEKS HIGHER PRICE FOR SHAREHOLDERS
March 20, 2013
New York, New York
Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Obagi Medical Products, Inc (OMPI). Obagi announced that it entered into a definitive merger agreement with Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) under which Valeant will acquire all of the outstanding common stock of Obagi for $19.75 per share in cash.
The investigation concerns whether the board of directors of Obagi breached its fiduciary duties by not engaging in a full and fair auction of the company to allow shareholders to obtain the highest price possible for their shares, while, at the same time, negotiating personal pay packages and benefits for themselves that will not be shared with shareholders.
If you are a shareholder of Obagi and would like additional information concerning this transaction at no cost or expense please contact us toll free at 1-877-772-3975 or email at contact @ tripplevy